

# Efficacy and safety of prostaglandin analogues in primary open-angle glaucoma or ocular hypertension patients

# A meta-analysis

Wenquan Tang, PhD<sup>a,b</sup>, Feng Zhang, PhD<sup>a</sup>, Ke Liu, PhD<sup>a</sup>, Xuanchu Duan, PhD<sup>a,c,d,\*</sup>

# Abstract

**Background:** To evaluated and compared the efficacy and safety of 3 prostaglandin analogues (0.005% latanoprost, 0.004% travoprost, and 0.03% bimatoprost) in treatment of primary open-angle glaucoma (POAG) or ocular hypertension (OHT).

**Methods:** PubMed, Embase, Cochrane library, Web of science, CNKI, Wanfang, and Vip database, published between January 1, 2000 and June 1, 2018, were systematically examined for randomized controlled trials (RCT) based on prostaglandin analogues for POAG or OHT treatment. Statistical analyses including weighted mean difference (WMD) calculation and odds ratio (OR) were performed using Review Manager Software version 5.3.

**Result:** The 17 studies were included in this analysis (N=2433 participants) with 1~12 months' follow-ups. The difference of intraocular pressure (IOP) reduction between latanoprost and travoprost group had not significant; there was significant difference of IOP reduction between latanoprost and bimatoprost group in the third month and sixth month; Travoprost was significantly different from bimatoprost in reducing IOP in the third month. Travoprost revealed an elevated risk of conjunctival hyperemia compared with latanoprost. An elevated risk of conjunctival hyperemia and growth of lashes compared with latanoprost. Bimatoprost shows lower ocular tolerability with higher incidence of side effects such as conjunctival hyperemia.

**Conclusions:** 0.03% bimatoprost appears more effective following long time use (3 and 6 month post-treatment) for IOP control compared to 0.005% latanoprost, and is more effective compared to 0.004% travoprost after being used for a certain period of time (3 months post-treatment); nevertheless, 0.005% latanoprost is better tolerated in patients with POAG or OHT.

**Abbreviations:** CIs = confidence intervals, IOP = intraocular pressure, OHT = ocular hypertension, OR = odds ratio, POAG = primary open-angle glaucoma, RCT = randomized controlled trial, WMD = weighted mean difference.

Keywords: bimatoprost, efficacy, glaucoma, latanoprost, meta-analysis, safety, travoprost

# 1. Introduction

Glaucoma is the leading cause of irreversible blindness in the world. Intraocular pressure (IOP) is considered a major risk factor for the development of glaucomatous optic neuropathy.<sup>[1–3]</sup>

Editor: Kou Yi.

The authors declare no conflicts of interest.

<sup>a</sup> Department of Ophthalmology, Second Xiangya Hospital, Central South University, <sup>b</sup> Department of Ophthalmology, Hunan Province Children' Hospital, <sup>c</sup> Aier School of Ophthalmology, Central South University, <sup>d</sup> Changsha Aier Eye Hospital, Changsha, Hunan, China.

<sup>\*</sup> Correspondence: Xuanchu Duan, Department of Ophthalmology, The Second Xiangya Hospital, Central South University, Changsha 410011, Hunan, China (e-mail: duanxchu@csu.edu.cn).

Copyright © 2019 the Author(s). Published by Wolters Kluwer Health, Inc. This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial License 4.0 (CCBY-NC), where it is permissible to download, share, remix, transform, and buildup the work provided it is properly cited. The work cannot be used commercially without permission from the journal.

Medicine (2019) 98:30(e16597)


Received: 17 April 2019 / Received in final form: 27 June 2019 / Accepted: 2 July 2019

http://dx.doi.org/10.1097/MD.000000000016597

Primary open-angle glaucoma (POAG) is the most common form of glaucoma in European and African populations.<sup>[4]</sup> Currently, lowering IOP is the only approved approach used to prevent glaucoma formation in ocular hypertensive (OHT) patients and to prevent or delay glaucomatous progression in POAG patients.<sup>[5]</sup> Management of elevated IOP is usually initiated with medical therapy, and the most popular drugs include — blockers, carbonic anhydrase inhibitors,  $\alpha$ -agonists, miotics, and prostaglandin analogs (PGs). PGs are the most potent ocular hypotensive medications used in the treatment of POAG and OHT.<sup>[6]</sup> Besides latanoprost (0.005%), travoprost (0.004%), and bimatoprost (0.03%), other popular PGs include tafluprost and unoprostone.

Several clinical trials have compared the efficacy and tolerance of different PGs.<sup>[15–31]</sup> However, the results of these studies have not been consistent. Over the last decade, few metaanalyses have evaluated PGs for glaucoma treatment;<sup>[7–9]</sup> nevertheless, they all have arrived to different conclusions. For example, Oghenowede Eyawo<sup>[7]</sup> has revealed that PGs have similar efficacy effect, but differing hyperemia effects. Moreover, Florent Aptel<sup>[8]</sup> has demonstrated that bimatoprost has a greater efficacy compared to latanoprost and travoprost; while according to Denis<sup>[9]</sup> travoprost and bimatoprost might have greater efficacy in lowering IOP compared to latanoprost. Nonetheless, these studies have been published almost a decade ago, which means there is an urgent need for further research.

This study was supported by National Natural Science Foundation of China (Grant No. 81670859), Science and Technology Foundation of Changsha, Hunan, China (Grant No. kh1801229), Natural Science Foundation of Hunan Province, China (Grant No. 2019JJ40001).



The aim of this study is to compare the efficacy and safety of 0.005% latanoprost, 0.004% travoprost and 0.03% bimatoprost in the treatment of patients with POAG or OHT. Metaanalysis of published clinical trials was conducted to compare the efficacy and/or safety of these 3 prostaglandin analogues.

# 2. Methods

## 2.1. Search strategy

This systematic review and meta-analysis were reported in accordance with the Preferred Reporting Items for Systematic

Reviews and Meta-Analyses (PRISMA) Statement.<sup>[10,11]</sup> Ethics approval is not applicable. This study is a research on research study.

We selected relevant studies published between January 1st, 2000 and June 1st, 2018 by searching PubMed, Embase, Cochrane library, Web of science, CNKI, Wanfang, and Vip databases. We applied no language restrictions and used the following Medical Subject Headings (MeSH) terms: "Glaucoma, Open-Angle", "Ocular Hypertension", "Latanoprost ", "Travoprost", "Bimatoprost", "Intraocular Pressure", "Randomized Controlled Trial". The commercial name of

# Table 1

Characteristics of the studies included in the meta-analysis.

Study	Region	Design	Comparison	No. of patients	Glaucoma types (POAG/OHT/other)	Mean age (yrs)	Sex (M/F%)	Duration
Arcieri <sup>[15]</sup> 2005	Brazil	RCT SB	LAT vs TRA vs BIM	15/17/16	34/0/30	67	34/30	6 mo
Birt <sup>[16]</sup> 2010					34/0/30	÷.		
	Europe	RCT SB	LAT vs TRA vs BIM	30/26/27	/	62	45/38	24 wk
Cantor <sup>[17]</sup> 2006	America	RCT SB	TRA vs BIM	81/76	108/48/1	65	81/76	6 mo
Cardascia <sup>[18]</sup> 2003	Italy	RCT DB	LAT vs TRA	9/9	18/0/0	52	9/9	6 mo
Cellini <sup>[19]</sup> 2004	Italy	RCT DB	LAT vs TRA vs BIM	20/20/20	60/0/0	64	32/28	6 mo
Faridi <sup>[20]</sup> 2010	America	RCT SB	LAT vs TRA vs BIM	42/40/40	35/55/32	68	65/57	6 mo
Gandolfi <sup>[21]</sup> 2001	Italy + America	RCT DB	LAT vs BIM	113/119	132/81/13	62	87/145	3 mo
Haili Huang <sup>[22]</sup> 2011	China	RCT NB	LAT vs TRA vs BIM	21/22/20	63/0/0	54	31/32	4 wk
Koz <sup>[23]</sup> 2007	Turkey	RCT DB	LAT vs TRA vs BIM	20/20/20	36/24/0	53	35/25	6 mo
Mishra <sup>[24]</sup> 2014	India	RCT SB	LAT vs TRA vs BIM	35/35/35	105/0/0	54	54/51	12 wk
Netland <sup>[25]</sup> 2001	America	RCT DB	LAT vs TRA	193/197	259/126/5	64	189/201	12 mo
Noecker <sup>[26]</sup> 2004	America	RCT SB	TRA vs BIM	15/16	28/3/0	65	11/20	3 mo
Noecker <sup>[27]</sup> 2006	America	RCT SB	TRA vs BIM	45/49	67/27/0	63	37/57	3 mo
Parrish <sup>[28]</sup> 2003	America	RCT SB	LAT vs TRA vs BIM	136/138/136	309/95/6	65	172/238	12 mo
Varma <sup>[29]</sup> 2008	America	RCT SB	LAT vs TRA vs BIM	136/138/136	509/95/6	65	172/238	12 wk
Xiangmei Kong <sup>[30]</sup> 2006	China	RCT SB	LAT vs TRA vs BIM	51/24/27	91/11/0	52	65/37	4 wk
Yildirim <sup>[31]</sup> 2008	Turkey	RCT SB	LAT vs TRA vs BIM	17/15/16	48/0/0	/	/	8 wk

BIM = bimatoprost, DB = double-blind, LAT = latanoprost, NB = non-blind, SB = single-blind, TRA = travoprost

	Lata	nopro	st	Travoprost				Mean Difference	Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Fixed, 95% CI	IV, Fixed, 95% CI
1 month									
Arcieri 2005	5.6	2.04	15	6	2.36	17	13.0%	-0.40 [-1.92, 1.12]	
Cardascia 2003	7.39	2.48	9	6.28	2.53	9	5.6%	1.11 [-1.20, 3.42]	
Netland 2001	6.77	3.7	193	7.47	3.7	197	55.8%	-0.70 [-1.43, 0.03]	
XM Kong 2006	9.28	3.29	51	8.25	3.03	24	13.2%	1.03 [-0.48, 2.54]	
HL Huang2011	3.6	2.46	21	3.8	2.74	22	12.4%	-0.20 [-1.75, 1.35]	
Subtotal (95% CI)			289			269	100.0%	-0.27 [-0.82, 0.28]	-
Heterogeneity: Chi2=	5.56, df	= 4 (P	= 0.23)	; I <sup>2</sup> = 28	%				
Test for overall effect	Z=0.96	(P = (	0.34)						
3 months									
Arcieri 2005	5.3	2.1	15	6.2	2.4	17	4.5%	-0.90 [-2.46, 0.66]	
Birt 2010	11	3.42	30	9.5	3.76	26	3.1%	1.50 [-0.39, 3.39]	
Cardascia 2003	7.56	2.49	9	7.56	2.5	9	2.1%	0.00 [-2.31, 2.31]	
Cellini 2004	8.5	3.46	20	9.2	3.46	20	2.4%	-0.70 [-2.84, 1.44]	
Faridi 2010	6.71	4.89	42	7.63	4.46	40	2.7%	-0.92 [-2.94, 1.10]	
Mishra 2014	7.3	1.1	35	7.6	1	35	45.5%	-0.30 [-0.79, 0.19]	
Parrish 2003	7	3.1	136	6.7	3.2	138	19.9%	0.30 [-0.45, 1.05]	
Varma 2008	8.6	2.96	136	7.9	3.34	138	19.8%	0.70 [-0.05, 1.45]	
Subtotal (95% CI)			423			423	100.0%	0.03 [-0.31, 0.36]	•
Heterogeneity: Chi2 =	10.29, d	lf = 7 (	P = 0.1	7);  2 = 3	2%				
Test for overall effect	Z=0.15	(P = (	0.88)						
6 months									
Arcieri 2005	5.4	2.07	15	6.3	2.39	17	12.0%	-0.90 [-2.45, 0.65]	
Birt 2010	10.6	3.5	30	10.1		26	8.3%	0.50 [-1.36, 2.36]	
Cellini 2004		3.46	20	9.1	3.46	20	6.2%	-0.80 [-2.94, 1.34]	
Faridi 2010	7.57	4.87	42	7.81	4.3	40	7.2%	-0.24 [-2.23, 1.75]	
Koz 2007		2.08	20		2.87	20	11.8%	0.50 [-1.05, 2.05]	
Netland 2001	7.17	3.65	193	7.14	3.65	197	54.5%	0.03 [-0.69, 0.75]	
Subtotal (95% CI)			320			320	100.0%	-0.06 [-0.59, 0.48]	-
Heterogeneity: Chi <sup>2</sup> =				; I= 09	6				
Test for overall effect	Z= 0.21	(P = 0	0.83)						
									7 2 2 2
									-4 -2 0 2
									Latanoprost Travoprost

#### Test for subaroup differences: Chi<sup>2</sup> = 0.81. df = 2 (P = 0.67). I<sup>2</sup> = 0%

Figure 2. Meta-analysis, forest graph of latanoprost versus travoprost for IOP-lowering effects (Trials subgrouped based on duration analyses). CI = confidence interval, SD = standard deviation.

the medication and the other text terms were also investigated. The complete search used for PubMed was: ((((Glaucoma, Open-Angle [MeSH] OR Glaucomas, Open-Angle [Title/ Abstract] OR Open-Angle Glaucoma [Title/ Abstract] OR Open-Angle Glaucomas [Title/Abstract] OR Glaucoma, Open Angle [Title/ Abstract] OR Glaucomas, Open Angle [Title/ Abstract] OR Open Angle Glaucoma [Title/Abstract] OR Open Angle Glaucomas [Title/ Abstract] AND (Ocular Hypertension [MeSH] OR Hypertension, Ocular [Title/ Abstract] OR Hypertensions, Ocular [Title/Abstract] OR Ocular Hypertensions [Title/Abstract]) AND (Latanoprost [Supplementary Concept] OR Xalatan [Title/Abstract] OR Pfizer brand of latanoprost [Title /Abstract] OR Travoprost [Mesh] OR Travatan ([Title/Abstract] OR Bimatoprost [Mesh] OR Latisse [Title/Abstract] OR Lumigan [Title/ Abstract]) AND (Intraocular Pressure [MeSH] OR Intraocular Pressures [Title/Abstract] OR Pressures intraocular [Title/ Abstract] OR Ocular Tension [Title/Abstract] OR Ocular Tensions [Title/Abstract] OR Tension Ocular [Title/Abstract] OR Tensions Ocular [Title/Abstract]) AND (Randomized Controlled Trial[Publication Type] OR Randomized [Title/ Abstract] OR Placebo [Title/Abstract])))). In addition, we performed a manual search from reference list of retrieved papers and review articles.

#### 2.2. Eligibility criteria and data collection

According to PICOS (Population, Intervention, Comparison, Outcome, Study design) principle, articles were selected based on the following criteria:

- (1) Population: patients with POAG or OHT, age >18, without sex, region, or race restriction;
- Intervention and Comparison: latanoprost, bimatoprost, and travoprost;
- (3) Outcome: at least 1 of the interested outcome variables discussed later was included;
- (4) Study design: randomized controlled trials (RCTs). Exclusion criteria were: cross-over experimental designs, multi-drug therapy, short duration of follow-up, lack of wash-out period before the trial started, reviews, and duplicate publications.

Trial eligibility and data extraction were performed by 2 investigators working independently; data were extracted using standardized forms. The following information was recorded from each study: authors of the trial, publication year, location of the study, study design (double-blind, single-blind), interventions, participants' characteristics (number, mean age, sex), length of follow-up, IOP value from baseline to endpoint, and adverse events. Disagreements were resolved by discussion or consensus involving a third investigator.

	Lata	nopro	st	Bim	Bimatoprost			Mean Difference	Mean Difference		
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Fixed, 95% CI	IV, Fixed, 95% Cl		
1 month								Contraction and the second second			
Arcieri 2005	5.6	2.04	15	5.7	2.13	16	34.9%	-0.10 [-1.57, 1.37]			
XM Kong 2006	9.28	3.29	51	9.41	4.1	27	23.4%	-0.13 [-1.92, 1.66]			
HL Huang2011	3.6	2.46	21	3.7	1.9	20	41.7%	-0.10 [-1.44, 1.24]			
Subtotal (95% CI)			87			63	100.0%	-0.11 [-0.97, 0.76]	-		
Heterogeneity: Chi <sup>2</sup> =	0.00, df	= 2 (P	= 1.00	); I <sup>2</sup> = 09	6						
Test for overall effect	Z= 0.24	(P=(	0.81)	17 - 50X.)							
3 months											
Arcieri 2005	5.3	2.1	15	5.8	2.13	16	4.0%	-0.50 [-1.99, 0.99]			
Birt 2010	11		30		3.34	27	2.9%	1.00 [-0.76, 2.76]			
Cellini 2004	8.5	3.46	20		3.38	20	2.0%	-0.30 [-2.42, 1.82]			
Faridi 2010	6.71	4.89	42	9.45	4.97	40	1.9%	-2.74 [-4.88, -0.60]	·		
Gandolfi 2001	7.7	3.04	113			119	14.4%	-0.50 [-1.28, 0.28]			
Mishra 2014	7.3	1.1	35	8.8	1.1	35	33.2%				
Parrish 2003	7	3.1	136	7.3	3.2	136	15.7%	-0.30 [-1.05, 0.45]			
Varma 2008	8.6	2.96	136	8.7	3.2	136	16.4%	-0.10[-0.83, 0.63]			
Yildirim 2008	4.8	1.31	17	5.5	1.51	16	9.4%	-0.70 [-1.67, 0.27]			
Subtotal (95% CI)			544			545	100.0%	-0.75 [-1.05, -0.45]	•		
Heterogeneity: Chi <sup>2</sup> =	20.38, 0	if = 8 (	P = 0.0	09); I= =	61%						
Test for overall effect	Z= 4.95	5 (P < (	0.0000	1)							
6 months											
Arcieri 2005	5.4	2.07	15	5.9	2.25	16	23.2%	-0.50 [-2.02, 1.02]			
Birt 2010	10.6	3.5	30	9.3	4.51	27	12.0%	1.30 [-0.81, 3.41]			
Cellini 2004	8.3	3.46	20	8.7	3.38	20	12.0%	-0.40 [-2.52, 1.72]			
Faridi 2010	7.57	4.87	42	9.23	4.91	40	12.0%	-1.66 [-3.78, 0.46]			
Koz 2007	6	2.08	20	7.5	1.59	20	40.8%	-1.50 [-2.65, -0.35]			
Subtotal (95% CI)			127			123	100.0%	-0.82 [-1.55, -0.09]	•		
Heterogeneity: Chi <sup>2</sup> =	6.14, df	= 4 (P	= 0.19	); I <sup>2</sup> = 35	%						
Test for overall effect	: Z= 2.19	) (P = (	0.03)								
									S (1) (2) (3)		
									-4 -2 0 2 4		
Test for subgroup dif	Toroncoc	Chiz	- 2.01	df = 2 //	P-02	7) 12 -	0.4%		-4 -2 0 2 Latanoprost Bimatoprost		

Figure 3. Meta-analysis, forest graph of latanoprost versus bimatoprost for IOP-lowering effects (Trials subgrouped based on duration analyses). CI = confidence interval, SD = standard deviation.

#### 2.3. Quality assessment

We performed quality assessment of trials with Cochrane bias risk assessment tool (The Cochrane Collaboration) for RCTs.<sup>[12]</sup> The risk of bias tool covers 6 domains of bias and 7 items: random sequence generation (selection bias), allocation concealment (selection bias), blinding of participants and personnel (performance bias), blinding of outcome assessment (detection bias), incomplete outcome date (attrition bias), selective reporting (reporting bias), other bias. The tool involves assigning a judgment of high, low, or unclear risk of bias for each item. Discrepancies in ratings were solved by discussion between 2 authors.

# 2.4. Statistical analyses

The analysis was conducted by Review Manager version 5.3 software (The Cochrane Collaboration).

For efficacy, the mean IOP reduction (IOPR) from baseline to endpoint was determined. For tolerability, adverse events were analyzed based on the following conditions: conjunctiva hyperemia, discomfort (itching, eye irritation, foreign body sensation), and growth of lashes. IOPR is continuous variables and side effects are dichotomous variables. Continuous outcomes were expressed as weighted mean difference (WMD), with values >0 favoring left prostaglandin analogue, and dichotomous outcomes as odds ratio (OR), with values <1 favoring left prostaglandin analogue. Both outcomes were reported with 95% confidence intervals (CIs).

For studies that only reported IOP at baseline and end-point, the IOPR and standard deviation (SD) of the IOPR (SD<sub>IOPR</sub>) were calculated according the following formula:<sup>[8]</sup>

$$IOPR = IOP_{baseline} - IOP_{endpoint} \tag{1}$$

$$SD_{IOPR} = (SD_{baseline}^2 + SD_{endpoint}^2 - SD_{baseline} + SD_{endpoint})^{1/2}$$
(2)

Heterogeneity of effective size across studies was tested using Cochran Q test, which was considered significant if P < .1.<sup>[13]</sup> This study also did I<sup>2</sup> testing to assess the magnitude of the heterogeneity between studies, with values that were greater than 50% being regarded as indicative of moderate-to-high heterogeneity.<sup>[14]</sup> If there was heterogeneity within these RCTs, random-effect model was selected. Otherwise, the fixed-effect model was used. And the subgroup analyses for each PG comparison were used. Additionally, this paper conducted a sensitivity analysis to evaluate the stability of meta-analysis.

	Tra	vopros	st	Bimatoprost				Mean Difference	Mean Difference		
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% Cl	IV, Random, 95% Cl		
1 month											
Arcieri 2005	6	2.36	17	5.7	2.13	16	23.0%	0.30 [-1.23, 1.83]			
Cantor 2006	6.5	3.2	81	8.2	3.3	76	32.9%	-1.70 [-2.72, -0.68]			
Noecker 2004	8.7	9.5	15	7.4	9.5	16	2.1%	1.30 [-5.39, 7.99]			
KM Kong 2006	8.25	3.03	24	9.41	4.1	27	17.1%	-1.16 [-3.12, 0.80]			
IL Huang 2011	3.8	2.74	22	3.7	1.9	20	24.9%	0.10 [-1.32, 1.52]			
Subtotal (95% CI)			159			155	100.0%	-0.64 [-1.64, 0.37]	-		
Heterogeneity: Tau <sup>2</sup> :	= 0.52; C	hi² = 7	.04. df=	= 4 (P =	0.13);	12 = 43°	36				
Test for overall effect											
3 months											
Arcieri 2005	6.2	2.4	17	5.8	2.13	16	4.4%	0.40 [-1.15, 1.95]			
Birt 2010	9.5	3.76	26	10	3.34	27	2.9%	-0.50 [-2.42, 1.42]			
Cantor 2006	6.2	3.2	81	7.6	3.3	76	10.2%	-1.40 [-2.42, -0.38]			
Cellini 2004	9.2	3.46	20	8.8	3.38	20	2.4%	0.40 [-1.72, 2.52]			
Faridi 2010	7.63	4.46	40	9.45	4.97	40	2.5%	-1.82 [-3.89, 0.25]			
Mishra 2014	7.6	1	35	8.8	1.1	35	41.9%	-1.20 [-1.69, -0.71]	-		
Noecker 2004	7.9	9.5	15	8.4	9.5	16	0.2%	-0.50 [-7.19, 6.19]			
Parrish 2003	6.7	3.2	138	7.3	3.2	136	18.2%	-0.60 [-1.36, 0.16]			
Varma 2008	7.9	3.34	138	8.7	3.2	136	17.4%	-0.80 [-1.57, -0.03]			
Subtotal (95% CI)			510			502	100.0%	-0.93 [-1.25, -0.60]	•		
Heterogeneity: Tau <sup>2</sup> :	= 0.00; C	hi² = 8	.08, df=	= 8 (P =	0.43);	$ ^2 = 1\%$					
Test for overall effect											
6 months											
Arcieri 2005	6.3	2.39	17	5.9	2.25	16	17.6%	0.40 [-1.18, 1.98]			
Birt 2010	10.1	3.58	26	9.3	4.51	27	12.1%	0.80 [-1.39, 2.99]			
Cantor 2006	5.7	3.2	81	7.1	3.3	76	25.0%	-1.40 [-2.42, -0.38]			
Cellini 2004	9.1	3.46	20	8.7	3.38	20	12.6%	0.40 [-1.72, 2.52]			
Faridi 2010	7.81	4.3	40	9.23	4.91	40	13.4%	-1.42 [-3.44, 0.60]			
Koz 2007	5.5	2.87	20	7.5	1.59	20	19.3%	-2.00 [-3.44, -0.56]			
Subtotal (95% CI)			204			199	100.0%	-0.71 [-1.65, 0.23]	-		
Heterogeneity: Tau <sup>2</sup> :	= 0.64; C	hi² = 9	.78, df =	= 5 (P =	0.08);	² = 49	%				
Test for overall effect	Z= 1.48	8 (P = 0	0.14)								
									<u> </u>		
									-4 -2 0 2 4		
									-4 -2 0 2 4 Travoprost Bimatoprost		

Figure 4. Meta-analysis, forest graph of travoprost versus bimatoprost for IOP-lowering effects (Trials subgrouped based on duration analyses). CI = confidence interval, SD = standard deviation.

# 3. Results

We identified 965 studies, of which 17 (with data for 2433 participants) were included in this analysis (Fig. 1). Trial duration ranged between 4 weeks and 12 months. The average age of patients was 52 to 68 years. Details of every study, such as the authors of trial, publication year, location of the study, study design (double-blind, single-blind), interventions, participants' characteristics in each study, are presented in Table 1.

### 3.1. Quality results

The quality of each RCTs were assessed by Cochrane bias risk assessment tool (data not shown). Two trials (11.8%) were judged at low risk of bias in every item; 4 trials (23.5%) were judged at high risk of bias in only 1 item; while 11 trials (64.7%) were judged at high or unclear risk of bias in at least 2 items. All these studies were RCTs. Seven trials (41.2%) had elaborated the generation of random sequence, while 10 (58.8%) had explained allocation concealment. Most studies were double-blinded, nevertheless, only 10 trials (58.8%) reported that appropriate methods had been used for assessors and participant blinding. Blinding of outcome assessment was a potential risk of bias in

23.5% of trials. Overall, the major potential sources of bias in the trials were selection and performance bias.

#### 3.2. Efficacy

To be able to more effectively compare the curative effect of these PGs, this study has adopted subgroup analysis according to the period drug was used. The result, expressed as absolute change in mmHg, showed that there was no significant difference between latanoprost and travoprost in reducing IOP at 1, 3, and 6 month post-treatment (WMD = -0.27, 95% CI -0.82 to 0.28, P=.34; WMD = 0.03, 95% CI -0.31 to 0.36, P=.88; and WMD = -0.06 95% CI -0.59 to 0.48, P=.83, respectively) (Fig. 2). In addition, no significant heterogeneity in the first month (heterogeneity P=.23 >.1,  $I^2=28\% <50\%$ ), third month (heterogeneity P=.17 >.1,  $I^2=32\% <50\%$ ) and the sixth-month post-treatment (heterogeneity P=.77 >.1,  $I^2=0\% <50\%$ ) between each RCTs was observed. Hence, the fixed model was adopted.

We respectively pooled 3, 9, and 5 trials assessing latanoprost to bimatoprost in the first, third, and sixth-month post-treatment (Fig. 3). The WMD across groups in the first month was -0.11 mmHg (95% CI, -0.97 to 0.76, P=.81,  $I^2=0\%$ , heterogeneity

Adverse events	Latanoprost (n=572)	Travoprost (n=602)	Bimatoprost (n = 508)
Conjunctival hyperemia	158 (27.62)	232 (38.54)	204 (40.16)
Discomfort (itching, eye irritation, foreign body sensation)	53 (9.27)	105 (17.44)	35 (6.89)
Growth of lashes	5 (0.87)	3 (0.50)	20 (3.94)
Total	216 (37.76)	340 (56.48)	259 (50.98)

 Table 2

 Summary of ocular adverse events, n (%).

P=.1), in the third month was -0.75 mmHg (95% CI, -1.05 to -0.45, P<.00001,  $I^2=61\%$ , heterogeneity P=.009), and in the sixth month was -0.82 mmHg (95% CI, -1.55 to -0.09, P=.03,  $I^2=35\%$ , heterogeneity P=.19). These data indicated that bimatoprost was more effective for IOP control in the third and sixth month for patients with POAG or OHT compared to travoprost. Moreover, the heterogeneity in the third month (heterogeneity P=.009<.1,  $I^2=61\%>50\%$ ) could be explained by clinical heterogeneity. Therefore, the fixed model was used.

The efficacy pooled estimates of IOPR between travoprost and bimatoprost based on the results of the RCTs included in the analyses are shown in Figure 4. Bimatoprost showed greater efficacy in lowering IOP in the third month (WMD=-0.93, 95% CI -1.25 to -0.60, P < .00001,  $I^2=1\%$ , heterogeneity P=.43) for patients with POAG or OHT. Similar effect was observed in the first month (WMD=-0.64, 95% CI -1.64 to 0.37, P=.21,  $I^2=43\%$ , heterogeneity P=.13), and the sixth month (WMD=-0.71, 95% CI -1.65 to 0.23, P=.14,  $I^2=49\%$ , heterogeneity P=.08) for patients treated with travoprost and bimatoprost. Moreover, a mild heterogeneity was found in the sixth month (heterogeneity P=.08 < 0.1,  $I^2=49\%$ ), which in turn couldn't be explained by clinical or methodological heterogeneity. Thus, the random model was adopted.

	Latanop	prost	Travop	rost		Odds Ratio	Odds Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% Cl	M-H, Random, 95% Cl
1 conjunctival hy	peremia						
Arcieri 2005	6	15	8	17	2.6%	0.75 [0.18, 3.06]	· · · · · · · · · · · · · · · · · · ·
Birt 2010	11	30	11	26	4.4%	0.79 [0.27, 2.31]	
Cardascia 2003	2	9	3	9	1.2%	0.57 [0.07, 4.64]	
Faridi 2010	3	42	4	40	2.1%	0.69 [0.14, 3.31]	
Mishra 2014	2	31	4	31	1.6%	0.47 [0.08, 2.75]	
Netland 2001	54	196	99	200	29.2%	0.39 [0.26, 0.59]	
Parrish 2003	64	136	80	138	22.5%	0.64 [0.40, 1.04]	
Subtotal (95% CI)		459		461	63.6%	0.52 [0.39, 0.69]	•
Total events	142		209				
Heterogeneity: Tau2:	= 0.00; Chi	<sup>2</sup> = 3.65	, df = 6 (P	= 0.72	); l² = 0%		
Test for overall effect	: Z = 4.56 (	P < 0.00	0001)				
2 discomfort							
Faridi 2010	5	42	5	40	2.9%	0.95 [0.25, 3.55]	
Mishra 2014	3	31	9	31	2.5%	0.26 [0.06, 1.08]	
Netland 2001	32	193	69	197	22.3%	0.37 [0.23, 0.60]	
Parrish 2003	13	136	12	138	7.6%	1.11 [0.49, 2.53]	
Subtotal (95% CI)		402		406	35.3%	0.56 [0.28, 1.13]	-
Total events	53		95				
Heterogeneity: Tau <sup>2</sup> :	= 0.27; Chi	<sup>2</sup> = 6.84	, df = 3 (P	= 0.08	); l² = 56%		
Test for overall effect	: Z = 1.63 (	P = 0.10	0)				
3 growth of lash	es						
Faridi 2010	0	42	2	40	0.5%	0.18 [0.01, 3.89]	
Parrish 2003	0	136	1	138	0.5%	0.34 [0.01, 8.31]	
Subtotal (95% CI)		178		178	1.0%	0.24 [0.03, 2.23]	
Total events	0		3				
Heterogeneity: Tau <sup>2</sup>	= 0.00; Chi	<sup>2</sup> = 0.07	, df = 1 (P	= 0.78	); l <sup>2</sup> = 0%		
Test for overall effect	: Z = 1.25 (	P = 0.21	1)				
Total (95% CI)		1039		1045	100.0%	0.50 [0.40, 0.63]	•
Total events	195		307				
Heterogeneity: Tau <sup>2</sup> :	= 0.00; Chi	<sup>2</sup> = 11.0	2, df = 12	(P = 0.	53); l² = 09	6	0.01 0.1 1 10 100
Test for overall effect	: Z = 5.94 (	P < 0.00	0001)				Favours (Latanoprost) Favours (Travoprost)
Test for subgroup di	ferences: (	Chi <sup>2</sup> = 0	.50, df = 2	P = 0	78), I <sup>2</sup> = 0	%	Favours (Latanoprost) Favours (Travoprost)

Figure 5. Meta-analysis, forest graph of latanoprost versus travoprost for ocular adverse effects (conjunctival hyperemia, discomfort and growth of lashes). CI = confidence interval.

	latanop		bimato			Odds Ratio	Odds Ratio
Study or Subgroup		Total	Events	Total	Weight	M-H, Fixed, 95% Cl	M-H, Fixed, 95% Cl
1 conjunctival hyp	peremia						
Arcieri 2005	6	15	12	16	4.3%	0.22 [0.05, 1.03]	
Birt 2010	11	30	12	27	4.9%	0.72 [0.25, 2.09]	
Faridi 2010	3	42	7	40	4.1%	0.36 [0.09, 1.51]	
Gandolfi 2001	16	113	43	119	22.2%	0.29 [0.15, 0.56]	
Mishra 2014	2	31	7	29	4.2%	0.22 [0.04, 1.15]	· · · · · · · · · · · · · · · · · · ·
Parrish 2003	64	136	94	136	30.7%	0.40 [0.24, 0.65]	
Subtotal (95% CI)		367		367	70.3%	0.36 [0.26, 0.51]	•
Total events	102		175				
Heterogeneity: Chi <sup>2</sup> =	2.95, df =	5 (P=	0.71); I <sup>2</sup> =	0%			
Test for overall effect:	Z= 5.87 (	P < 0.0	0001)				
2 discomfort							
Faridi 2010	5	42	7	40	3.9%	0.64 [0.18, 2.20]	
Mishra 2014	3	31	5	29	2.9%	0.51 [0.11, 2.38]	
Parrish 2003	13	136	19	136	10.6%	0.65 [0.31, 1.38]	
Subtotal (95% CI)		209	655	205	17.4%	0.63 [0.35, 1.13]	-
Total events	21		31			•	
Heterogeneity: Chi <sup>2</sup> =	0.07, df =	2 (P=	0.96); I <sup>2</sup> =	0%			
Test for overall effect:							
3 growth of lashe	s						
Faridi 2010	0	42	1	40	0.9%	0.31 [0.01, 7.83]	
Gandolfi 2001	5	113		119	8.6%	0.32 [0.11, 0.91]	
Parrish 2003	0	136	4	136	2.8%	0.11 [0.01, 2.02]	• • • • • • • • • • • • • • • • • • • •
Subtotal (95% CI)		291		295	12.3%	0.27 [0.11, 0.69]	-
Total events	5		20				
Heterogeneity: Chi <sup>2</sup> =	0.48. df =	2 (P=		0%			
Test for overall effect:				20.20			
Total (95% CI)		867		867	100.0%	0.40 [0.30, 0.53]	•
Total events	128		226				
Heterogeneity: Chi <sup>2</sup> =		11 (P =		= 0%			
Test for overall effect:							0.02 0.1 1 10 50
			0001/				Favours [Latanoprost] Favours [Bimatoprost]

Figure 6. Meta-analysis, forest graph of latanoprost versus bimatoprost for ocular adverse effects (conjunctival hyperemia, discomfort and growth of lashes). Cl = confidence interval.

# 3.3. Tolerability

Table 2 describes the overall ocular adverse events, including conjunctival hyperemia, discomfort (itching, eye irritation, foreign body sensation) and growth of lashes. Briefly, the data showed that travoprost led to a higher proportion than latanoprost in the conjunctival hyperemia (OR=0.52, 95% CI 0.39 to 0.69, P < .00001;  $I^2 = 0\%$ , heterogeneity P = .72, respectively) (Fig. 5). Furthermore, latanoprost and travoprost have similar incidence rate of discomfort (OR=0.56, 95% CI 0.28-1.13, P=.10,  $I^2=56\%$ , heterogeneity P=.08) and growth of lashes (OR=0.24, 95% CI 0.03 to 2.23, P=.21,  $I^2=0\%$ , heterogeneity P = .78). Moreover, moderate heterogeneity in the discomfort (heterogeneity P = .08 < .1,  $I^2 = 56\%$ ) was observed. Thus, the random model was adopted. To sum up, travoprost revealed an elevated risk of adverse effects compared with latanoprost (OR = 0.50, 95% CI 0.40–0.63, P < .00001,  $I^2 = 0\%$ , heterogeneity P = .53).

All of the adverse events showed a significant difference between latanoprost and bimatoprost, except for discomfort (OR=0.63, 95% CI 0.35–1.13, P=.12,  $I^2=0\%$ , heterogeneity P=.96) (Fig. 6). Moreover, no significant heterogeneity between each RCTs was found, thus the fixed model was used. Bimatoprost shows lower ocular tolerability with higher incidence of conjunctival hyperemia (OR=0.64, 95% CI 0.46–0.88, P=.007,  $I^2=0\%$ , heterogeneity P=.89) compared with travoprost (Fig. 7). In terms of discomfort and growth of lashes, travoprost and bimatoprost have similar incidence rate (OR=1.01, 95% CI 0.62–1.65, P=.97,  $I^2=16\%$ , heterogeneity P=.31; OR=0.59, 95% CI 0.14–2.59, P=.47,  $I^2=39\%$ , heterogeneity P=.20). Moreover, no significant heterogeneity between each RCTs was found, therefore the fixed model was used.

#### 3.4. Sensitivity analysis

To analyze the consistency and robustness of the results, a sensitivity examination was performed (data not shown). For assessing the influence of each individual clinical trial included in the meta-analysis, each study was excluded at a time and the analysis was performed again to determine the change in the WMD or OR. The punctual estimators for WMD varied between -0.47 and 0.27 in the latanoprost-travoprost efficacy analysis first-month post-treatment; between -0.14 and 0.3 third month after treatment, and between -0.16 and 0.06 6-months after

	Travopr	ost	Birnatop	rost		Odds Ratio	Odds Ratio
Study or Subgroup		Total	Events	Total	Weight	M-H, Fixed, 95% Cl	M-H. Fixed. 95% Cl
1 conjunctival hy	peremia						
Arcieri 2005	8	17	12	16	5.2%	0.30 [0.07, 1.30]	
Birt 2010	11	26	12	27	5.4%	0.92 [0.31, 2.72]	
Cantor 2006	12	81	16	76	11.1%	0.65 [0.29, 1.49]	
Faridi 2010	4	40	7	40	5.0%	0.52 [0.14, 1.95]	
Mishra 2014	4	31	7	29	5.0%	0.47 [0.12, 1.80]	
Noecker 2004	4	15	3	16	1.7%	1.58 [0.29, 8.61]	
Noecker 2006	7	45	10	49	6.4%	0.72 [0.25, 2.08]	
Parrish 2003	80	138	94	136	31.5%	0.62 [0.38, 1.01]	
Subtotal (95% CI)		393		389	71.2%	0.64 [0.46, 0.88]	•
Total events	130		161				
Heterogeneity: Chi <sup>2</sup> =	2.91, df =	7 (P=)	0.89); I <sup>2</sup> =	0%			
Test for overall effect:							
2 discomfort							
Cantor 2006	6	81	2	76	1.5%	2.96 [0.58, 15.14]	
Faridi 2010	5	40	7	40	4.8%	0.67 [0.19, 2.33]	
Mishra 2014	9	31	5	29	2.9%	1.96 [0.57, 6.76]	2
Noecker 2004	1	15	Ő	16	0.3%	3.41 [0.13, 90.49]	
Noecker 2006	3	45	2	49	1.4%	1.68 [0.27, 10.54]	
Parrish 2003	12	138	19	136	13.8%	0.59 [0.27, 1.26]	
Subtotal (95% CI)		350		346	24.9%	1.01 [0.62, 1.65]	+
Total events	36		35				
Heterogeneity: Chi <sup>2</sup> =		5 (P =		16%			
Test for overall effect:				1010			
3 growth of lashe	S						
Faridi 2010	2	40	1	40	0.8%	2.05 [0.18, 23.59]	
Parrish 2003	ĩ	138	4	136	3.2%	0.24 [0.03, 2.18]	
Subtotal (95% CI)		178		176	3.9%	0.59 [0.14, 2.50]	
Total events	3		5				
Heterogeneity: Chi <sup>2</sup> =	-	1 (P=)	-	39%			
Test for overall effect:							
Total (95% CI)		921		911	100.0%	0.73 [0.56, 0.95]	•
Total events	169	321	201	311	100.070	0.10 [0.00, 0.00]	•
Heterogeneity: Chi <sup>2</sup> =		- 15 /0		- 0%			
Test for overall effect:				- 076			0.01 0.1 i 10 10
rescior overall effect.			2) 2.43. df = 2				Favours (Travoprost) Favours (Bimatoprost)

Figure 7. Meta-analysis, forest graph of travoprost versus bimatoprost for ocular adverse effects (conjunctival hyperemia, discomfort and growth of lashes). CI = confidence interval.

treatment, after excluding 1 by 1 each original clinical trial. During the sixth month of latanoprost-bimatoprost efficacy analysis, when excluding the Faridi's trial,<sup>[20]</sup> the result of this meta-analysis changed from favoring bimatoprost to showing no significant difference between latanoprost and bimatoprost. In the travoprost- bimatoprost efficacy analysis, after excluding each RCTs, the results were the same. None of the clinical trials included in the meta-analysis had an important impact on the global estimation of the OR, except for the meta-analysis of discomfort in comparison between latanoprost and travoprost. When excluding Parrish's trial,<sup>[28]</sup> the result of this metaanalysis changed. In general, the obtained results of meta-analysis were stable.

# 4. Discussion

Results of this meta-analysis suggested that bimatoprost is more effective in controlling IOP compared to latanoprost following longer treatment (3 and 6 months), and is more effective compared to travoprost when used for a certain period of time (3-month post-treatment) in patients with POAG or OHT. Latanoprost and travoprost showed similar efficacy in lowering IOP, nevertheless, latanoprost was better tolerated in patients with POAG or OHT. These conclusions provide an effective theoretical basis for clinical medication.

As shown in Figures 2–4, this trial has produced robust and consistent findings which suggested that bimatoprost has the highest efficacy for patients with POAG or OHT. Furthermore, the comparison of adverse effects including conjunctival hyperemia, discomfort (itching, eye irritation, foreign body sensation) and growth of lashes between 3 PGs are shown in Figures 5–7. Briefly, the data suggested that conjunctival hyperemia occurs more frequently in patients treated with bimatoprost and travoprost compared to those treated with latanoprost. Besides, bimatoprost has shown to be associated with a higher incidence of growth of lashes compared to lashes compared to latanoprost.

Several studies have proved that prostaglandin analogues are more effective compared to brimonidine or timolol<sup>[32,33]</sup> in lowering IOP. Nonetheless, the comparisons of these PGs, have

generated different conclusions. Some clinical trials<sup>[22,28,30]</sup> have revealed that these 3 PGs, that is, travoprost. bimatoprost and latanoprost have the same efficacy. Contrary, other trials<sup>[17,25,26]</sup> have proved that bimatoprost is more effective in lowering the IOP compared to latanoprost and travoprost. Travoprost has high selectivity and affinity for FP receptor, and it has been shown to be more effective for black patients.<sup>[34]</sup> The differences in characteristics of population, region and methodological issues may account for these results.

A comparison between 3 PGs, that is, travoprost, Bimatoprost, and latanoprost have been previously published.<sup>[7–9]</sup> However, these meta-analysis have reported different conclusions and had certain limitations. For example, none of these studies included subgroup analysis. Moreover, in some studies, significant heterogeneity and publication bias was observed, which in turn might have affected the outcome. By contrast, this study used the strict methods to investigate the comparison between latanoprost, travoprost, and bimatoprost in terms of efficacy and safety. Therefore, this study provides more useful advice to ophthalmologists.

To sum up, the findings suggested that different complex factors, that is, difference in corneal permeability and intraocular drug metabolism,<sup>[35–37]</sup> have influenced the treatment outcome in patients with POAG or OHT. This might be mainly because the 3 drugs have different affinity for different types of FP receptors;<sup>[38]</sup> latanoprost and travoprost have shown strong affinity for prostaglandin E1 (EP1), EP3, and prostaglandin FP (PGFP) receptor, while bimatoprost for PGFPR, but also certain affinity for EP1 and EP3 receptor.<sup>[39]</sup> Different affinity causes different efficacy. Because of the different affinity for FP receptor between these 3 PGs, bimatoprost has shown to be more effective in controlling IOP compared to latanoprost and travoprost, even if, fewer side effects were observed in patients treated with latanoprost. Also, the different drug concentration (0.005% latanoprost, 0.004% travoprost, 0.03% bimatoprost) contributed to the terminal results, that is, higher concentration is positively correlated with drug efficacy, but also with higher side effects. According to these findings, bimatoprost was used at the highest concentrations, which in turn caused better efficacy and worse adverse effects compared to latanoprost and travoprost. Besides, the observed effects could also be attributed to different formula. In fact, bimatoprost is a prostamide analogue which has been synthesized,<sup>[40]</sup> while latanoprost and travoprost are both prostaglandin analogues.

The prediction of individual medicine and their susceptibility is extremely difficult. Currently, there are no screening methods which could identify the optimum PG for individual cases. Therefore, according to our findings, it would be better to use bimatoprost for patients with POAG or OHT as they can tolerate the local side effects like conjunctival congestion.

Limitation of this meta-analysis is the unknown long-term durability of this treatment; included trials lasted more than 6 months. What's more, only 4 studies had a large sample size, while all other RCTs were based on a small sample size. Lastly, the publication bias cannot be excluded from the subgroup analysis.

#### 5. Conclusion

The results of this meta-analysis suggested that 0.03% bimatoprost might be more effective compared to 0.005% latanoprost and 0.004% travoprost for lowering IOP in patients with POAG and OHT, even though latanoprost has low

incidence of ocular adverse effects. In clinical, the appropriate use of medicine is very important for patients. Lower the intraocular pressure of glaucoma patient to ideal level is essential to them. While there are no definite guides to direct ophthalmologists use prostaglandins (PAGs). These results may be useful for determining the optimal strategy for individual patients. Based on these findings, we recommend the use of bimatoprost for patients who can tolerate the side effects. In fact, everyone has a different response to PGs. Therefore, it is better for ophthalmologists considering all aspects for every patient. Personal treatment would be a trend in the future.

#### Acknowledgments

The authors appreciate the work of editors and reviewers.

#### **Author contributions**

Conceptualization: Xuanchu Duan. Data curation: Wenquan Tang, Feng Zhang. Formal analysis: Wenquan Tang, Feng Zhang. Funding acquisition: Xuanchu Duan. Investigation: Xuanchu Duan. Methodology: Wenquan Tang, Xuanchu Duan. Resources: Xuanchu Duan. Software: Wenquan Tang, Feng Zhang. Supervision: Xuanchu Duan. Writing – original draft: Wenquan Tang. Writing – review & editing: Ke Liu, Xuanchu Duan. Wenquan Tang orcid: 0000-0002-1413-9252.

### References

- Jutley G, Luk SM, Dehabadi MH, et al. Management of glaucoma as a neurodegenerative disease. Neurodegener Dis Manag 2017;7:157–72.
- [2] Jia X, Yu J, Liao SH, et al. Biomechanics of the sclera and effects on intraocular pressure. Int J Ophthalmol 2016;9:1824–31.
- [3] Kim YH, Jung SW, Nam GE, et al. High intraocular pressure is associated with cardioMetabolic risk factors in South Korean men: Korean National Health and Nutrition Examination Survey, 2008-2010. Eye(Lond) 2014;28:672–9.
- [4] Tham YC, Li X, Wong TY, et al. Global prevalence of glaucoma and projections of glaucoma burden through 2040: a systematic review and meta-analysis. Ophthalmology 2014;121:2081–90.
- [5] Lusthaus JA, Goldberg I. Investigational and experimental drugs for intraocular pressure reduction in ocular hypertension and glaucoma. Expert Opin Inv Drugs 2016;25:1201–8.
- [6] Song W, Yu QZ, Du C. Physiological mechanisms of prostaglandin analogues on lowing intraocular pressure. Guo Yan Za Zhi 2017; 17:884–7.
- [7] Eyawo O, Nachega J, Lefebvre P, et al. Efficacy and safety of prostaglandin analogues in patients with predominantly primary open-angle glaucoma or ocular hypertension: a meta-analysis. Clin Ophthalmol 2009;3:447–56.
- [8] Aptel F, Cucherat M, Denis P. Efficacy and tolerability of prostaglandin analogs: a meta-analysis of randomized controlled clinical trials. J Glaucoma 2008;17:667–73.
- [9] Denis P, Lafuma A, Khoshnood B, et al. A meta-analysis of topical prostaglandin analogues intra-ocular pressure lowering in glaucoma therapy. Curr Med Res Opin 2007;3:601–8.
- [10] Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med 2009;151:264–9.
- [11] Hutton B, Salanti G, Caldwell DM, et al. The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations. Ann Intern Med 2015;162:777–84.

- [12] Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-hand book.org.
- [13] Higgins JP, Thompson SG, Deeks JJ, et al. Measuring inconsistency in meta-analyses. BMJ 2003;327:557–60.
- [14] Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med 2002;21:1539–58.
- [15] Arcieri ES, Santana A, Rocha FN, et al. Blood-aqueous barrier changes after the use of prostaglandin analogues in patients with pseudophakia and aphakia: a 6-month randomized trial. Arch Ophthalmol 2005; 123:186–92.
- [16] Birt CM, Buys YM, Ahmed, et al. Prostaglandin efficacy and safety study undertaken by race (the PRESSURE study). J Glaucoma 2010;19: 460–7.
- [17] Cantor LB, Hoop J, Morgan L, et al. Intraocular pressure-lowering efficacy of bimatoprost 0.03% and travoprost 0.004% in patients with glaucoma or ocular hypertension. Br J Ophthalmol 2006;90:1370–3.
- [18] Cardascia N, Vetrugno M, Trabucco T, et al. Effects of travoprost eye drops on intraocular pressure and pulsatile ocular blood flow: a 180-day, randomized, double-masked comparison with latanoprost eye drops in patients with open-angle glaucoma. Curr Therap Res 2003;64:389–400.
- [19] Cellini M, Caramazza R, Bonsanto D, et al. Prostaglandin analogs and blood-aqueous barrier integrity: a flare cell meter study. Ophthalmologica 2004;218:312–7.
- [20] Faridi UA, Saleh TA, Ewings P, et al. Comparative study of three prostaglandin analogues in the treatment of newly diagnosed cases of ocular hypertension, open-angle and normal tension glaucoma. Clin Exp Ophthalmol 2010;38:678–82.
- [21] Gandolfi S, Simmons ST, Sturm R, et al. Three-month comparison of bimatoprost and latanoprost in patientswith glaucoma and ocular hypertension. Adv Ther 2001;18:110–21.
- [22] Huang HL, Sun XH, Xiao M. Comparison of intraocular pressure reducing effects of three prostaglandin eyedrops in open-angle glaucoma. Chin J Ophthalmol 2011;47:109–13.
- [23] Koz OG, Ozsoy A, Yarangumeli A, et al. Comparison of the effects of travoprost, latanoprost and bimatoprost on ocular circulation: a 6month clinical trial. Acta Ophthalmol Scand 2007;85:838–43.
- [24] Mishra D, Sinha BP, Kumar MS. Comparing the efficacy of latanoprost (0.005%), bimatoprost (0.03%), travoprost (0.004%), and timolol (0.5%) in the treatment of primary open angle glaucoma. Korean J Ophthalmol 2014;28:399–407.
- [25] Netland PA, Landry T, Sullivan EK, et al. Travoprost compared with latanoprost and timolol in patients with open-angle glaucoma or ocular hypertension. Am J Ophthalmol 2001;132:472–84.

- [26] Noecker RJ, Earl ML, Mundorf T, et al. Bimatoprost 0.03% versus travoprost 0.004% in black Americans with glaucoma or ocular hypertension. Adv Ther 2004;20:121–8.
- [27] Noecker RJ, Earl ML, Mundorf TK, et al. Comparing bimatoprost and travoprost in black Americans. Curr Med Res Opin 2006;22:2175–80.
- [28] Parrish RK, Palmberg P, Sheu WP. A comparison of latanoprost, bimatoprost, and travoprost in patients with elevated intraoeular pressure: a 12-week, randomized, masked-evaluator multicenter study. Am J Ophthalmol 2003;135:688–703.
- [29] Varma R, Hwang LJ, Grunden JW, et al. Inter-visit intraocular pressure rang: an alternative parameter for assessing intraocular pressure control in clinical trials. Am J Ophthalmology 2008;2:336–42.
- [30] Kong XM, Sun XH, Meng FR. A comparison of the ocular hypotensive efficacy of three prostaglandin analog. Chin J Optometry Ophthalmol 2006;8:228–30.
- [31] Yildirim N, Sahin A, Gultekin S. The effect of latanoprost, bimatoprost, and travoprost on circadian variation of intraocular pressure in patients with open-angle glaucoma. J Glaucoma 2008;17:36–9.
- [32] Dzhumataeva ZA. Prostaglandin analogues in glaucoma treatment. Vestn Oftalmol 2016;132:62–7.
- [33] Thelen U, Schnober D, Scholzel S, et al. Long-term cost and efficacy analysis of latanoprost versus timolol in glaucoma patients in Germany. Int J Ophthalmol 2013;6:155–9.
- [34] Netland PA, Robertscal SM, Sullivan EK, et al. Response to travoprost in black and nonblack patients with open-angle glaucoma or ocular hypertension. Adv Ther 2003;20:149–63.
- [35] Ramsay E, Del Amo EM, Toropainen E, et al. Corneal and conjunctival drug permeability: Systematic comparison and pharmacokinetic impact in the eye. Eur J Pharm Sci 2018;119:83–9.
- [36] Krishnaswami V, Kandasamy R, Alagarsamy S, et al. Biological macromolecules for ophthalmic drug delivery to treat ocular diseases. Int J Biol Macromol 2018;110:7–16.
- [37] Saini M, Vanathi M, Dada T, et al. Ocular surface evaluation in eyes with chronic glaucoma on long term topical antiglaucoma therapy. Int J Ophthalmol 2017;10:931–8.
- [38] Sharif NA, Kelly CR, Crider JY, et al. Ocular hypotensive FP prostaglandin (PG) analogs:PG receptor subtype binding affinities and selectivities, and agonist potencies at FP and other PG receptors in cultured cells. J Ocul Pharmacol Ther 2003;19:501–15.
- [39] Ota T, Aihara M, Saeki T, et al. The effects of prostaglandin analogues on prostanoid EP1, EP2, and EP3 receptor-deficient mice. Invest Ophthalmol Vis Sci 2006;47:3395–9.
- [40] Brennan N, Dehabadi MH, Nair S, et al. Efficacy and safety of bimatoprost in glaucoma and ocular hypertension in non-responder patients. Int J Ophthalmol 2017;10:1251–4.